The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided positive scientific advice for the development plan of the dupilumab biosimilar GS101 injection. The CHMP endorsed the proposed quality and clinical development strategy and agreed that, based on solid evidence for similarity, such a tailored clinical approach may be acceptable without a comparative efficacy study (CES).
The Company will fully consider the scientific advice from the EMA CHMP in GS101’s subsequent development, optimizing and improving the similarity assessment plan and comparative PK study design. The Company will maintain proactive communication with the EMA to advance the global registration and marketing process of GS101 injection.
2026.03.15
——————–
The company announces that the Investigational New Drug application for its self-developed dupilumab biosimilar, GS101, has received implicit approval from the Center for Drug Evaluation of the National Medical Products Administration. The approval was recorded on January 13, 2026 (Acceptance No.: CXSL2500955). The proposed indication is the treatment of atopic dermatitis.
2025.11.07
——————–
On November 7, 2025, Jiangsu Genscend Biopharma Co., Ltd received the Acceptance Notice issued by the National Medical Products Administration (NMPA). The IND application for a Dupixent biosimilar (Project code:GS101) has been accepted, with acceptance number: CXSL2500955.
2025.11.07
——————–
Address:
· Building 1, No. 907 Yaocheng Avenue, Hailing District, Taizhou City, Jiangsu Province
· Shanghai Branch : Room 1808, Building A, No.100 Zunyi Road, Changning District, Shanghai
Email: jsjx@jxingbio.com
Copyright © 2025 江苏景行生物医药有限公司 All Rights Reserved.
苏ICP备2026007812号.
